Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Gracell Raises $100 Million in Private Placement for Trials of CAR-T Candidates

publication date: Aug 7, 2023

Gracell Biotechnologies, a Suzhou-San Diego CAR-T company, raised $100 million in a private placement that could rise to $150 million if participants exercise options for additional shares. Gracell is developing a portfolio of CAR-T candidates based on its FasTCAR platform, which features next-day delivery of autologous CAR-T therapies, and its TruUCAR off-the-shelf technology platform. Gracell said the capital will support the company into the second half of 2026. The private placement priced the company’s ADSs at $3.60, and the warrants will purchase an ADS at $5.58.  More details....

Stock Symbol: (NSDQ: GRCL)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital